Mymd Pharmaceuticals (NASDAQ:QCLS) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Mymd Pharmaceuticals (NASDAQ:QCLS) from a sell rating to a strong sell rating in a research report report published on Sunday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday, August 7th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Mymd Pharmaceuticals Stock Down 4.3%

Shares of NASDAQ:QCLS opened at $2.69 on Friday. The firm has a market cap of $11.22 million, a P/E ratio of -0.77 and a beta of 2.16. The company has a 50 day moving average price of $3.40. Mymd Pharmaceuticals has a fifty-two week low of $2.50 and a fifty-two week high of $10.13.

Mymd Pharmaceuticals (NASDAQ:QCLS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.